Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Paclitaxel in Advanced GI Tumors
NCT03977077Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2019
- Primary completion
- Oct 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nab-paclitaxel in esophageal cancer, gastric cancer (GC), pancreatic cancer (PC) and 1 more, sponsored by Henan Cancer Hospital. Primary endpoint: Progression Free Survival at 2 years. Status: unknown.
02
Drugs
nab-paclitaxel
03
Conditions
esophageal cancergastric cancer (GC)pancreatic cancer (PC)gallbladder cancer
Beyond the preview
Go deeper on NCT03977077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977077.